Jane Street’s Fulcrum Therapeutics FULC Stock Holding History

Jane Street’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$162K	Buy	+44,200	New	+$269K	﹤0.01%	10287
2025 Q1	–	Sell	-27,500	Closed	-$129K	–	9792
2024 Q4	$129K	Sell	27,500 -50,600	-65%	-$187K	﹤0.01%	8647
2024 Q3	$279K	Buy	+78,100	New	+$579K	﹤0.01%	8150
2023 Q2	–	Sell	-12,500	Closed	-$35.6K	–	8961
2023 Q1	$35.6K	Buy	+12,500	New	+$112K	﹤0.01%	8535
2022 Q1	–	Sell	-17,500	Closed	-$310K	–	10529
2021 Q4	$310K	Buy	17,500 +8,000	+84%	+$158K	﹤0.01%	8106
2021 Q3	$268K	Buy	+9,500	New	+$180K	﹤0.01%	8401

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jane Street's FULC Position: Q2 2026 in Review

Jane Street increased its Fulcrum Therapeutics (FULC) stake by 614% in Q2 2026, buying an estimated $11.6M and bringing the position to 2,217,498 shares worth $8.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Jane Street first reported a position in FULC in Q3 2021 and has held it in 19 quarters since. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Jane Street held 2,217,498 shares of Fulcrum Therapeutics worth $8.12M as of Q2 2026.
Jane Street bought 1,907,081 Fulcrum Therapeutics shares in Q2 2026, an estimated $11.6M.
Fulcrum Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3090 holding.
Jane Street first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 19 quarters since.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.